Applying our pre‐clinical findings, we then treated two patients (one with a non‐small‐cell lung cancer and one with a renal cell carcinoma) whose tumours harboured these previously uncharacterised MET alterations with cabozantinib, a type II MET TKI, and observed clinical responses. The gene discussed is MET; the disease is hereditary clear cell renal cell carcinoma.